share_log

Independent Director Deborah Autor Sold A Bunch Of Shares In Amneal Pharmaceuticals

Independent Director Deborah Autor Sold A Bunch Of Shares In Amneal Pharmaceuticals

独立董事黛博拉·奥特出售了Amneal Pharmicals的大量股票
Simply Wall St ·  05/22 06:08

We'd be surprised if Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shareholders haven't noticed that the Independent Director, Deborah Autor, recently sold US$256k worth of stock at US$6.74 per share. The eyebrow raising move amounted to a reduction of 29% in their holding.

如果Amneal Pharmicals, Inc.(纳斯达克股票代码:AMRX)的股东没有注意到独立董事黛博拉·奥特最近以每股6.74美元的价格出售了价值25.6万美元的股票,我们会感到惊讶。此次举措使他们的持股量减少了29%。

Amneal Pharmaceuticals Insider Transactions Over The Last Year

去年的Amneal Pharmicals内幕交易

Notably, that recent sale by Deborah Autor is the biggest insider sale of Amneal Pharmaceuticals shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$6.69. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

值得注意的是,黛博拉·奥特最近的出售是我们去年对Amneal Pharmicals股票的最大一次内幕出售。因此,显而易见的是,一位内部人士认为以当前6.69美元左右的价格卖出是合适的。我们通常不喜欢看到内幕销售,但是销售价格越低,我们就越担心。我们注意到,此次销售的价格约为当前价格,因此尽管这不是一个好兆头,但这并不是一个主要问题。

In the last year Amneal Pharmaceuticals insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

去年,Amneal Pharmicals内部人士没有购买任何公司股票。下图显示了去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!

insider-trading-volume
NasdaqGS:AMRX Insider Trading Volume May 22nd 2024
纳斯达克股票代码:AMRX 内幕交易量 2024 年 5 月 22 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

如果你喜欢买入内部人士正在买入的股票,而不是卖出,那么你可能会喜欢这份免费的公司名单。(提示:它们中的大多数都在雷达下飞行)。

Insider Ownership Of Amneal Pharmaceuticals

Amneal制药的内部所有权

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Amneal Pharmaceuticals insiders own about US$1.1b worth of shares (which is 53% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

我喜欢看看内部人士在一家公司拥有多少股票,以帮助我了解他们与内部人士的看法。较高的内部所有权通常会使公司领导层更加关注股东的利益。Amneal Pharmicals内部人士拥有价值约11亿美元的股份(占该公司的53%)。我喜欢看到这种程度的内部所有权,因为它增加了管理层考虑股东最大利益的机会。

So What Does This Data Suggest About Amneal Pharmaceuticals Insiders?

那么这些数据对Amneal Pharmicals Insiders有什么启示呢

An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, Amneal Pharmaceuticals has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.

一位内部人士最近出售了股票,但他们一直没有买入。在过去的一年里,没有任何能让我们感到安慰的购买。尽管内部人士确实拥有该公司的大量股份(这很好),但我们对他们交易的分析并不能使我们对公司充满信心。因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。例如,Amneal Pharmicals有3个警告信号(其中一个不容忽视),我们认为你应该知道。

But note: Amneal Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但请注意:Amneal Pharmicals可能不是最好的买入股票。因此,来看看这份投资回报率高、债务低的有趣公司的免费清单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发